0000899243-22-032731.txt : 20221004
0000899243-22-032731.hdr.sgml : 20221004
20221004173019
ACCESSION NUMBER: 0000899243-22-032731
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221003
FILED AS OF DATE: 20221004
DATE AS OF CHANGE: 20221004
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Maduck Sean
CENTRAL INDEX KEY: 0001698310
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-50679
FILM NUMBER: 221293263
MAIL ADDRESS:
STREET 1: C/O CORCEPT THERAPEUTICS INCORPORATED
STREET 2: 149 COMMONWEALTH DRIVE
CITY: MENLO PARK
STATE: CA
ZIP: 94025
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CORCEPT THERAPEUTICS INC
CENTRAL INDEX KEY: 0001088856
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 770487658
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 149 COMMONWEALTH DRIVE
CITY: MENLO PARK
STATE: CA
ZIP: 94025
BUSINESS PHONE: 650.688.8803
MAIL ADDRESS:
STREET 1: 149 COMMONWEALTH DRIVE
CITY: MENLO PARK
STATE: CA
ZIP: 94025
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-10-03
0
0001088856
CORCEPT THERAPEUTICS INC
CORT
0001698310
Maduck Sean
C/O CORCEPT THERAPEUTICS INCORPORATED
149 COMMONWEALTH DRIVE
MENLO PARK
CA
94025
0
1
0
0
See Remarks
Common Stock
2022-10-03
4
M
0
25000
3.29
A
81462
D
Common Stock
2022-10-03
4
S
0
25000
25.64
D
56462
D
Common Stock
10000
I
See Footnote
Common Stock
10000
I
See Footnote
Stock option (right to buy)
3.29
2022-10-03
4
M
0
25000
0.00
D
2025-02-18
Common Stock
25000
57602
D
The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction.
Includes 922 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $25.64 to $25.66. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.
Represents the shares held by Duckhill Capital, LLC of which the reporting person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
Represents the shares held by Sean and Molly Maduck Living Trust of which the reporting person is a co-trustee.
Fully exercisable.
President, Corcept Endocrinology
The power of attorney under which this form was signed is on file with the Commission.
/s/ Joseph Douglas Lyon, as attorney-in-fact for Sean Maduck
2022-10-04